Sobi buys rights to AstraZeneca infant drug for $1.5 billion upfront

AstraZeneca has taken another step to refocus on priority drugs by selling U.S. rights to a treatment for infant lung infections to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion.